Triple GLP-1/GIP/NPY2 Agonist BI 3034701 Enters Phase II in Obesity
Boehringer Ingelheim's BI 3034701 targets three distinct metabolic receptors simultaneously, positioning it as a potent…
Boehringer Ingelheim's BI 3034701 targets three distinct metabolic receptors simultaneously, positioning it as a potent…
The V012 data add clinical weight to acellular tissue engineering, a frontier with implications for bioactive and regen…
The Amsterdam showcase signals growing operator appetite for workflow-integrated AI diagnostics — a trend with downstre…
As clean-label beauty-from-outside converges with nutricosmetics, topical actives targeting neck laxity signal a formul…
As better-burger operators eye experiential retail, the Calgary Stampede debut tests consumer appetite for premium QSR …
As climate-driven health events intensify, payer-side interventions intersect with functional nutrition's hydration, el…
The rural New York network adds capacity ahead of peak visitor demand, broadening primary-care touchpoints in an unders…
The deal signals growing crossover between sleep health and cardiometabolic wellness — a channel nutraceutical brands a…
Focal segmental glomerulosclerosis remains underdiagnosed; the campaign signals growing crossover between rare disease …
The accreditation signals growing regulatory rigor around nutrigenomic and precision-nutrition testing services in the …
With average QSR lunch tickets pushing $15–$20, value-positioned functional wraps are carving a new lane in the better-…
The device falls outside functional foods and nutraceuticals; operators and editors should note this release is not ali…